G0465 Insurance Policy Changes

HCPCS G0465 is officially defined as "Autologous platelet rich plasma (prp) or other blood-derived product for diabetic chronic wounds/ulcers, using an fda-cleared device for this indication, (includes as applicable administration, dressings, phlebotomy, centrifugation or mixing, and all other preparatory procedures, per treatment)." HCPCS G0465 is referenced in 3 tracked payer policy changes from Blue Cross Blue Shield of Rhode Island, Aetna, and 1 other payer. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS G0465 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.